438 related articles for article (PubMed ID: 35288362)
1. Cell type-specific mechanistic target of rapamycin-dependent distortion of autophagy pathways in lupus nephritis.
Caza T; Wijewardena C; Al-Rabadi L; Perl A
Transl Res; 2022 Jul; 245():55-81. PubMed ID: 35288362
[TBL] [Abstract][Full Text] [Related]
2. Blockade of Treg Cell Differentiation and Function by the Interleukin-21-Mechanistic Target of Rapamycin Axis Via Suppression of Autophagy in Patients With Systemic Lupus Erythematosus.
Kato H; Perl A
Arthritis Rheumatol; 2018 Mar; 70(3):427-438. PubMed ID: 29161463
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus.
Kato H; Perl A
J Immunol; 2014 May; 192(9):4134-44. PubMed ID: 24683191
[TBL] [Abstract][Full Text] [Related]
4. Rab4A-directed endosome traffic shapes pro-inflammatory mitochondrial metabolism in T cells via mitophagy, CD98 expression, and kynurenine-sensitive mTOR activation.
Huang N; Winans T; Wyman B; Oaks Z; Faludi T; Choudhary G; Lai ZW; Lewis J; Beckford M; Duarte M; Krakko D; Patel A; Park J; Caza T; Sadeghzadeh M; Morel L; Haas M; Middleton F; Banki K; Perl A
Nat Commun; 2024 Mar; 15(1):2598. PubMed ID: 38519468
[TBL] [Abstract][Full Text] [Related]
5. Podocytes and autophagy: a potential therapeutic target in lupus nephritis.
Zhou XJ; Klionsky DJ; Zhang H
Autophagy; 2019 May; 15(5):908-912. PubMed ID: 30755075
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial Dysfunction in the Liver and Antiphospholipid Antibody Production Precede Disease Onset and Respond to Rapamycin in Lupus-Prone Mice.
Oaks Z; Winans T; Caza T; Fernandez D; Liu Y; Landas SK; Banki K; Perl A
Arthritis Rheumatol; 2016 Nov; 68(11):2728-2739. PubMed ID: 27332042
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus.
Lai ZW; Borsuk R; Shadakshari A; Yu J; Dawood M; Garcia R; Francis L; Tily H; Bartos A; Faraone SV; Phillips P; Perl A
J Immunol; 2013 Sep; 191(5):2236-46. PubMed ID: 23913957
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial Dysfunction in Systemic Lupus Erythematosus with a Focus on Lupus Nephritis.
Halfon M; Tankeu AT; Ribi C
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892349
[TBL] [Abstract][Full Text] [Related]
9. Glomerular mTORC1 activation was associated with podocytes to endothelial cells communication in lupus nephritis.
Liu X; Mao Z; Yuan M; Li L; Tan Y; Qu Z; Chen M; Yu F
Lupus Sci Med; 2023 May; 10(1):. PubMed ID: 37147021
[TBL] [Abstract][Full Text] [Related]
10. Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis.
Rafael-Vidal C; Altabás I; Pérez N; Mourino Rodríguez C; Pego-Reigosa JM; Garcia S
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33514066
[TBL] [Abstract][Full Text] [Related]
11. Mangiferin Attenuates Murine Lupus Nephritis by Inducing CD4+Foxp3+ Regulatory T Cells via Suppression of mTOR Signaling.
Liang CL; Lu W; Zhou JY; Chen Y; Zhang Q; Liu H; Qiu F; Dai Z
Cell Physiol Biochem; 2018; 50(4):1560-1573. PubMed ID: 30359968
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic mTOR blockade in systemic autoimmunity: Implications for antiviral immunity and extension of lifespan.
Geier C; Perl A
Autoimmun Rev; 2021 Dec; 20(12):102984. PubMed ID: 34718162
[TBL] [Abstract][Full Text] [Related]
13. Increased autophagy is cytoprotective against podocyte injury induced by antibody and interferon-α in lupus nephritis.
Qi YY; Zhou XJ; Cheng FJ; Hou P; Ren YL; Wang SX; Zhao MH; Yang L; Martinez J; Zhang H
Ann Rheum Dis; 2018 Dec; 77(12):1799-1809. PubMed ID: 30209031
[TBL] [Abstract][Full Text] [Related]
14. mTOR signaling: A pivotal player in Treg cell dysfunction in systemic lupus erythematosus.
Zhao X; Wang S; Wang S; Xie J; Cui D
Clin Immunol; 2022 Dec; 245():109153. PubMed ID: 36265758
[TBL] [Abstract][Full Text] [Related]
15. Renal mTORC1 activation is associated with disease activity and prognosis in lupus nephritis.
Mao Z; Tan Y; Tao J; Li L; Wang H; Yu F; Perl A; Zhao M
Rheumatology (Oxford); 2022 Aug; 61(9):3830-3840. PubMed ID: 35040950
[TBL] [Abstract][Full Text] [Related]
16. Effect of mycophenolate and rapamycin on renal fibrosis in lupus nephritis.
Zhang C; Chan CCY; Cheung KF; Chau MKM; Yap DYH; Ma MKM; Chan KW; Yung S; Chan TM
Clin Sci (Lond); 2019 Aug; 133(15):1721-1744. PubMed ID: 31358596
[TBL] [Abstract][Full Text] [Related]
17. Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.
Perl A
Nat Rev Rheumatol; 2016 Mar; 12(3):169-82. PubMed ID: 26698023
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin reverses the senescent phenotype and improves immunoregulation of mesenchymal stem cells from MRL/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR signaling pathway.
Gu Z; Tan W; Ji J; Feng G; Meng Y; Da Z; Guo G; Xia Y; Zhu X; Shi G; Cheng C
Aging (Albany NY); 2016 May; 8(5):1102-14. PubMed ID: 27048648
[TBL] [Abstract][Full Text] [Related]
19. B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis-Role in Pathogenesis and Effect of Immunosuppressive Treatments.
Yap DYH; Chan TM
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835612
[TBL] [Abstract][Full Text] [Related]
20. HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE.
Caza TN; Fernandez DR; Talaber G; Oaks Z; Haas M; Madaio MP; Lai ZW; Miklossy G; Singh RR; Chudakov DM; Malorni W; Middleton F; Banki K; Perl A
Ann Rheum Dis; 2014 Oct; 73(10):1888-97. PubMed ID: 23897774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
